Key result
Higher nonfasting triglycerides linked to increased coronary heart disease and cardiovascular risk.
In 1996 a meta-analysis was published showing that an increase in plasma triglyceride (TG) levels was associated with an increase in CHD risk, even after adjustment for high density lipoprotein cholesterol (HDL-C) levels. Very recently, two studies were published that further extent the early observation and showed the importance of nonfasting plasma triglyceride (TG) levels in the prediction of risk on coronary heart disease (CHD). In the current review we have summarized all available evidence obtained in clinical studies showing that treatment guidelines should reconsider to include nonfasting TG in their risk assessments as nonfasting TG levels may better predict CVD risk.
No takes yet. Share an insight, caveat, or question.
Harchaoui et al. (2009) conducted a review in Coronary Heart Disease (CHD) / Cardiovascular Disease (CVD). Nonfasting plasma triglyceride (TG) levels was evaluated on Coronary heart disease / Cardiovascular disease risk. Nonfasting plasma triglyceride levels are associated with an increased risk of coronary heart disease and may better predict overall cardiovascular risk.
Synapse has enriched 5 related papers. Consider them for comparative context: